1. Home
  2. GDO vs EQ Comparison

GDO vs EQ Comparison

Compare GDO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global Corporate Defined Opportunity Fund Inc.

GDO

Western Asset Global Corporate Defined Opportunity Fund Inc.

HOLD

Current Price

$11.73

Market Cap

89.6M

Sector

Finance

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$0.86

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDO
EQ
Founded
2009
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.6M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
GDO
EQ
Price
$11.73
$0.86
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
39.4K
433.6K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
9.81%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.21
$0.27
52 Week High
$13.04
$2.35

Technical Indicators

Market Signals
Indicator
GDO
EQ
Relative Strength Index (RSI) 55.98 35.50
Support Level $11.62 $0.81
Resistance Level $11.78 $0.92
Average True Range (ATR) 0.13 0.10
MACD 0.03 0.00
Stochastic Oscillator 93.75 10.98

Price Performance

Historical Comparison
GDO
EQ

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: